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Objectives We evaluated the potential association between plasma high-mobility group box 1
(HMGB1) levels and outcome in patients with ST-segment elevation myocardial infarction (STEMI)
treated with primary percutaneous coronary intervention.
Background The positive effect of reperfusion after STEMI may be compromised by ischemic/reper-
fusion injury. HMGB1 is released by necrotic cells and, in pre-clinical studies, has been implicated to
play a role in myocardial ischemic/reperfusion injury.
Methods The study included 141 STEMI patients, with acute occlusion of the left anterior descend-
ing coronary artery successfully treated with percutaneous coronary intervention. Plasma HMGB1
levels were measured by enzyme-linked immunoadsorbent assay at admission. Forty-two healthy
individuals served as control subjects.
Results After a median of 10 months of follow-up, 13 STEMI patients died. There were no signiﬁ-
cant differences with regard to baseline variables between the group of patients who survived and
those who died. Baseline HMGB1 levels were increased in STEMI patients when compared with con-
trol subjects. Furthermore, the STEMI patients who died had higher HMGB1 levels than those who
survived. After adjusting for age, sex, troponin I, and creatine kinase-myocardial band, we found
that a doubling of HMGB1 concentrations increased the risk of mortality by 75% (hazard ratio: 1.75;
95% conﬁdence interval: 1.1 to 2.8).
Conclusions Plasma HMGB1 levels are elevated in STEMI patients compared with healthy control
subjects. Furthermore, after a follow-up period of 10 months, plasma HMGB1 levels are shown to be
independently associated with increased mortality in STEMI patients treated with PCI. These data
suggest that plasma HMGB1 may be used as a new prognostic biomarker in STEMI patients. (J Am
Coll Cardiol Intv 2011;4:281–6) © 2011 by the American College of Cardiology Foundation
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282The prevalence of acute and chronic ischemic heart disease,
ischemic-reperfusion (I/R) injury and heart failure, reaches
up to 8% in the Western countries and accounts for more
than 30% of all deaths (1). It is now well established that the
most effective treatment strategy for acute myocardial in-
farction is immediate reperfusion by primary percutaneous
coronary intervention (PCI) or thrombolytic agents (2,3).
Nevertheless, patients surviving an acute myocardial infarc-
tion have a 10% risk of dying and a 25% risk of heart failure
within 1 year (4). Patients with ST-segment elevation
myocardial infarction (STEMI) treated with primary PCI
or thrombolytic agents experience ischemia followed by
reperfusion and are consequently at risk of I/R injury
(5–10). Paradoxically, I/R injury can limit the effect of
reperfusion because of several mechanisms, for example,
oxidative stress and an intense inflammatory response (5–10).
High-mobility group box 1 (HMGB1), a potent factor
for the innate host defense
and/or tissue repair, has recently
been suggested to be a key player
in I/R injury, as evaluated in
pre-clinical studies (11). In addi-
tion to being a ligand for toll-like
receptors 4 (TLR4) and 9 (TLR9)
(12,13), HMGB1 is also a potent
ligand for the receptor for ad-
vanced glycation end products
(14,15). Data from some recently
published pre-clinical experiments
(15–19) and cross-sectional clin-
ical observations (15,19,20) have
indicated a pivotal role of HMGB1
in ischemic heart disease. However,
the precise role of HMGB1 in I/R
injury in the heart is uncertain
and HMGB1 has been sug-
gested to be a risk factor for
heart injury, and accordingly involved in the pathogenesis,
but by contrast also to hold cardioprotective properties
(15–20). Accordingly, the aim of this study was to examine
the prognostic value of plasma HMGB1 levels, collected at
admission, in STEMI patients treated with primary PCI, in
terms of subsequent mortality after a median follow-up
period of 10 months.
Methods
Patients. The Gentofte University Hospital serves a catch-
ment population of 1.2 million citizens (with respect to
PCI, this is more than 20% of the total Danish population)
referred directly or via noninvasive centers. More than 650
primary PCIs are performed annually. Inclusion criteria in
the present study were: significant (minimum 2-mm) ST-
Abbreviations
and Acronyms
CK-MB  creatine kinase-
myocardial band
HMGB1  high-mobility
group box 1
I/R  ischemic/reperfusion
LAD  left anterior
descending branch
MI  myocardial infarction
PCI  percutaneous
coronary intervention
STEMI  ST-segment
elevation myocardial
infarction
TIMI  Thrombolysis In
Myocardial Infarction
TLR  toll-like receptorsegment elevation in at least 2 contiguous precordial leads p(V1 to V6) of the electrocardiogram; significant increase in
cardiac markers (troponin I 0.5 g/l and creatine kinase-
yocardial band [CK-MB] 5 g/l); 12 h from onset of
ymptoms to primary PCI; acute occlusion of the anterior
escending branch (left anterior descending branch [LAD])
f the left coronary artery (pre-procedure Thrombolysis
n Myocardial Infarction [TIMI] flow grade 1); and
uccessful primary PCI (post-procedure TIMI flow grade
). Exclusion criteria were: previous myocardial infarction
MI), history of heart failure, and current infectious or
nflammatory disease. From October 2006 to July 2008, 141
atients fulfilled the inclusion criteria. Forty-two healthy
ndividuals without ischemic heart disease, randomly se-
ected from a large community-based database (21), served
s control subjects. All patients gave informed consent.
Primary PCI. The primary PCI was performed according to
nternational guidelines using pre-treatment with 10,000 IU
f unfractionated heparin, 300 to 500 mg acetyl salicylic
cid, and 300 to 600 mg clopidogrel. The transfemoral
pproach was used with 6- or 8-F sheath, conventional
evices, and Iomeron contrast fluid (Bracco, Minneapolis,
innesota). The occluded LAD was stented in all cases by
or more drug-eluting or bare-metal stents. Glycoprotein
Ib/IIIa inhibitors were used at the discretion of the
perator. Distal protection or thrombectomy devices were
ot used (22,23). Subsequent medical treatment included
nti-ischemic, lipid-lowering, and antithrombotic drugs
ccording to guidelines.
Measurement of plasma HMGB1. Peripheral arterial blood
was drawn from the femoral sheath at the beginning of the
procedure, thus avoiding contamination with contrast fluid.
Blood was allocated to different containers including 4-ml
ethylenediamine tetraacetic acid containers and within 0.5 h
centrifuged at 10,000 revolutions/min for 10 min. Plasma
was stored in Nunc Cryo-tubes (Nunc, Roskilde, Denmark)
at 80°C. Plasma HMGB1 levels were measured by an
enzyme-linked immunoadsorbent assay (Shino-Test Corpora-
tion, Kanagawa, Japan). The intraassay and interassay coeffi-
cients of variance were 5% and 10%, respectively.
Follow-up and study end points. Information regarding
eath was collected from the National Person Identification
egistry. The median follow-up time was 10 months and
he study end point was all-cause mortality. Follow-up was
00% complete.
Statistics. Baseline characteristics were compared between
he group of STEMI patients who died and those who
urvived by the Fisher exact test for dichotomous variables
nd by Student unpaired t test and Mann-Whitney U test
or continuous Gaussian and non-Gaussian distributed
ariables, respectively. Comparisons among all 3 groups
STEMI groups and controls) were done by chi-square
est and parametric 1-way analysis of variance. Linear
nd logistic regression analyses were used to evaluate any
otential associations between baseline variables and level of
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283HMGB1. Associations between prognostic variables and
end points were examined by univariate and multivariate
Cox proportional hazards regression models. Before per-
forming adjusted Cox regression, the assumptions of linear-
ity and proportional hazards were ensured. To avoid func-
tional form misspecification, HMGB1 concentrations were
transformed logarithmically (using the binary logarithm).
The reported means of HMGB1 represent geometric means.
The p values 0.05 were considered of statistical signifi-
ance. SPSS for Windows (version 17.0, IBM Corp.,
omers, New York) was used.
esults
Patient characteristics and outcome. This study included
141 STEMI patients with culprit lesion in the LAD artery
(all mid- or proximal LAD). All patients had pre-procedure
TIMI flow grade 1 and a successful primary PCI with a
post-procedure TIMI flow grade 3. After a median
follow-up of 10 months, 13 STEMI patients died from
cardiovascular deaths. The clinical characteristics of the
STEMI patients who survived, the STEMI patients who died,
and the 42 healthy control subjects are given in Table 1.
Although the healthy control subjects were significantly
younger than the STEMI patients, there were no significant
differences according to baseline variables between the 2
STEMI groups.
HMGB1 levels and predictive value. HMGB1 was collected
nitially during the PCI procedure. As shown in Figure 1A,
TEMI patients had significantly higher levels than healthy
Table 1. Baseline Variables for 141 STEMI Patients (Dead or Alive at Follo
STEMI Patien
Dead at Follow-Up
(n  13)
Age, yrs 68.8 13.4
Male, % 53.4
Current smoker, % 30.8
Hypertension, % 23.1
Diabetes, % 0
Hereditary IHD, % 30.8
Hypercholesterolemia, % 84.6
Symptom-to-balloon, min 150 (110–380)
Door-to-balloon, min 30 (20–35)
Glycoprotein IIb/IIIa, % 22.7
Multivessel disease,‡ % 27.2
Complex lesions,§ % 51.6
Drug-eluting stents, % 76.9
Peak TnI 242 (39–427)
Peak CK-MB 430 (175–909)
Values are mean  SD, %, or median (interquartile range). The data, being normally distribute
symptom-to-balloon and door-to-balloon) are given as median with IQR. *Analysis of variance for
‡Multivessel disease: 2- or 3-vessel disease; §Complex lesion: Type B lesion.CK-MB creatine kinase-myocardial band; IHD ischemic heart disease; STEMI ST-segment elevatioontrol subjects did (2.9 g/l [range: 2.6 to 3.2 g/l] vs. 1.3
g/l [1.1 to 1.5 g/l]). Moreover, as illustrated in Figure
1B, STEMI patients who died during follow-up had sig-
nificantly higher HMGB1 levels than surviving STEMI
patients did (4.8 g/l [range: 3.1 to 7.5 g/l] vs. 2.9 g/l
range: 2.6 to 3.2 g/l]). We evaluated potential associa-
tions between baseline variables and level of HMGB1 using
linear and logistic regression, and no significant associations
were found. Univariate Cox regression analyses revealed
that for each doubling of the HMGB1 level, the risk of
mortality increased by 101% (HR: 2.01, 95% CI: 1.3 to 3.1;
p 0.002). After adjustment for age and sex, high HMGB1
levels significantly predicted mortality (HR: 1.85, 95% CI:
1.2 to 2.9; p  0.003) (Fig. 2) (Table 2). Even after
djustment for age, sex, troponin I, and CK-MB, high
MGB1 levels significantly predicted mortality (HR: 1.75,
5% CI: 1.1 to 2.8; p  0.022).
iscussion
The major new finding of the present study is that high
HMGB1 levels significantly predict mortality in STEMI
patients treated with primary PCI. We found that a dou-
bling of plasma HMGB1 levels was associated with a 75%
increased risk of mortality, even after adjustment for age,
sex, troponin I, and CK-MB. This finding may be a clinically
important and relevant finding because of the potential role
of HMGB1 as a biomarker of outcome in STEMI patients,
as well as a factor potentially involved in myocardial I/R
injury and ischemic pre-conditioning. Furthermore, our data
and 42 Healthy Control Subjects
p Value
Healthy Control
Subjects
(n  42) p Value
t Follow-Up
 128)
 15.5 0.15 52.0 12.9 0.001*
75.6 0.09 76.2 0.22†
48.4 0.22 33.3 0.13†
28.1 0.70
7.8 0.30
27.3 0.79
83.6 0.92
(115–258) 0.88
(17–33) 0.64
15.4 0.55
25.0 0.87
53.8 0.86
85.8 0.39
(51–302) 0.40
(96–467) 0.09
iven as mean with 95% confidence interval, whereas data not being normally distributed (i.e.,
ups (comparison of means); †Fisher exact test for all 3 groups (comparison of proportions rates);w-Up)
ts
Alive a
(n
68.6
170
25
160
252
d are g
all 3 gron myocardial infarction; TnI troponin I.
ce 
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284confirm the results of 2 previously published cross-sectional
studies of elevated plasma HMGB1 levels in STEMI patients
compared with that in healthy control subjects.
HMGB1 is a DNA binding protein that plays several
roles in intra- and extracellular processes. HMGB1 has been
found to play an important role in inflammatory responses
and tissue repair. Furthermore, HMGB1 has been sug-
gested to play a pivotal role in the response to ischemia or
I/R in various organs. Accordingly, this role is subject to
intensive research in various diseases such as sepsis, acute
Figure 1. Plasma HMGB1 Levels
(A) Plasma high-mobility group box 1 (HMGB1) levels in ST-segment elevation
jects (n  42); Student t test 0.001. (B) Plasma HMGB1 levels in STEMI patien
follow-up (n  128) versus healthy control subjects (n  42); analysis of varian
Figure 2. Chi-Square Evaluation of the Predictive Value of HMGB1
Chi-square evaluation of the predictive value of HMGB1: adjusted for age,
sex, and CK-MB (yellow); adjusted for age, sex, and troponin I (blue); and
adjusted for age, sex, CK-MB, and troponin I (red). CK-MB  creatine
kinase-myocardial band; HMGB1  high-mobility group box 1.hepatic injury, cerebral infarcts, acute lung injury, and myo-
cardial ischemia (11,14–20,24–26). HMBG1 is passively
released from necrotic cells or by activated inflammatory
cells and leads to increased production of proinflammatory
mediators. Interestingly, HMBG1 has been shown to be an
important ligand for receptor for advanced glycation end
products and TLR4 and TLR9 (12,13).
The potential role of HMGB1 in myocardial I/R injury
has been suggested in some recent pre-clinical studies
(15–19). In studies in mice and rats, increased heart and/or
circulating HMGB1 levels have been reported after exper-
ardial infarction (STEMI) patients (all, n  141) versus healthy control sub-
o were dead at follow-up (n  13) versus STEMI patients who were alive at
0.01. Bars are geometric means and boxes are 95% conﬁdence intervals.
Table 2. Multivariable Cox’s Regression Analyses Estimating
Hazard Ratio for Mortality
End Point: Mortality
HMGB1
(per Each Doubling of HMGB1)
HR (95% CI) p Value
Model 1
Univariate 2.01 (1.3–3.1) 0.002
Model 2
Adjusted for age and sex 1.87 (1.2–2.9) 0.003
Model 3
Adjusted for age, sex, and CK-MB 1.68 (1.1–2.7) 0.028
Model 4
Adjusted for age, sex, and TnI 1.82 (1.2–3.0) 0.002
Model 5
Adjusted for age, sex, CK-MB, and TnI 1.75 (1.1–2.8) 0.022
Hazard ratios (HRs) were estimated using HMGB1 as a continuous variable, with steps at each
doubling of HMGB1 concentration.
CI confidence interval; HMBG1 high-mobility group box 1; other abbreviations as inmyoc
ts whTable 1.
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285imental MI (15–19). However, when it comes to the associa-
tion between HMGB1 levels and the outcome, as measured
by cardiac function and mortality, the published pre-clinical
data are contradictory. In the study by Oozawa et al. (16),
administration of a neutralizing monoclonal antibody against
HMGB1 in rats exposed to cardiac I/R injury resulted in a
further increase in troponin I, norepinephrine, and infarct
size, which indicate a positive effect of HMGB1 in myo-
cardial scarring. Additional support of a beneficial effect of
HMGB1 comes from a study in transgenic mice with a
cardiac-specific HMGB1 expression (17). In this study,
cardiac overexpression of HMGB1 was associated with
improved cardiac function and survival and cardiac function
after experimental MI. In another study in mice with MI,
local administration of HMGB1 to the injured myocardium
induced myocardial regeneration (18). In contrast, 2 studies
support a deleterious effect of HMGB1 in myocardial I/R
injury. In one study (15) in mice, administration of HMGB1
in mice exposed to I/R injury of the heart worsened the
tissue damage, whereas administration of a functional
HMGB1 antagonist significantly reduced markers of tissue
damage and infarct size. In a recent study, administration of
a neutralizing anti-HMGB1 antibody to rats exposed to
experimental MI reduced the infarct size, a thinning and
expansion of the infarct scar, and a marked hypertrophy of
the noninfarcted area (19). These contradictory pre-clinical
results indicate diverse effects of HMGB1 in ischemia and
may be an indicator that HMGB1 is capable of exerting
both beneficial and deleterious effects to the heart during
the complex process of tissue remodeling after I/R injury.
Along these lines, a recent study suggested that the heter-
ogeneity in the reported effects of HMGB1 might be due to
different mechanisms during conditions characterized either
of permanent ischemia or by ischemia reperfusion (27).
Accordingly, during permanent ischemia, the infracted,
necrotic myocardium might benefit from local increased
HMGB1 levels via proliferation of cardiac c-kit stem cells.
In addition, total blockade of HMGB1 results in impaired
healing (16). Reperfusion by contrast is accompanied by an
extensive release of free radicals and an enhanced inflam-
matory response, including neutrophils and macrophages
infiltrations, causing further cardiac damage and signifi-
cantly higher HMGB1 levels. Therefore, HMGB1 might
act as a double edge in post-infarction inflammatory response.
Few clinical studies have been published on the potential
association between myocardial ischemia and HMGB1
(15,19,20). Interestingly, all of these studies indicated that
high HMGB1 levels were associated with impaired out-
come, which supports the findings in our study. In a study
by Goldstein et al. (20), serum HMGB1 levels were
measured in 9 patients with acute coronary syndrome and
these levels were elevated compared with that of healthy
volunteers. In the pre-clinical study by Andrassy et al. (15),
the investigators reveal that they have unpublished datashowing elevated plasma HMGB1 levels in STEMI pa-
tients at admission. In the recent study by Kohno et al. (19),
including 35 STEMI patients, serum HMGB1 levels were
increased transiently within the first 7 days after admission
with a peak value of 12 h. In the same study, there was an
indication of an association between elevated HMGB1
levels and the risk of cardiac rupture and in-hospital death.
However, these data were only based on data from 3 and 2
patients, respectively, and the data were not adjusted for
potential confounders, for example, age and sex (19). Fi-
nally, in the study by Giallauria et al. (27), which included
67 STEMI patients, the investigators reported a significant
association between increased circulating HMGB1 levels
and autonomic dysfunction, by the demonstration of a low
post-exercise heart rate in post-infarction patients per-
formed 3 to 4 weeks after STEMI.
In the present study, we report elevated circulating levels
of HMGB1 in STEMI patients when compared with
relevant control subjects, and thereby confirm data from
some recent cross-sectional studies (15,19,20). In addition,
we report for the first time—in a larger clinical study—an
association between high HMGB1 levels and mortality rate
in STEMI patients. To exclude as many confounders as
possible, we deliberately included a homogeneous group of
well-characterized STEMI patients without previous MI,
history of heart failure, or current infectious/inflammatory
disease and with a successful primary PCI. Future studies
are warranted to examine the usability of plasma HMGB1
as a predictor of mortality, in more heterogeneous groups of
myocardial ischemic patients, including both patients with
STEMI/non-STEMI and with varying degrees of success-
ful reperfusion. To adjust for potential confounders, we
performed multivariable analysis. Because we wanted to
maintain a solid Cox model, we decided only to adjust for
age, sex, troponin I, and CK-MB. We have tested for
potential associations between HMGB1 and other baseline
variables, and no such were found. Furthermore, no signif-
icant differences in baseline variables were found between
the 2 groups.
Conclusions
Emerging pre-clinical and clinical data support the notion
that HMBG1 may play a role in I/R-myocardial injury. In
the present study, we confirmed previous reports that
patients with STEMI have elevated levels of HMGB1
when compared with healthy subjects. Furthermore, we
show for the first time that high HMGB1 levels in STEMI
patients sampled at admission predict an increased mortality
risk. These data suggest that plasma HMGB1 may be used
as a new biomarker of mortality in STEMI patients.
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